Gleaning information from more than 100 experts in the field of cancer diagnosis, prognosis, and therapy worldwide, Cancer Biomarkers: Non-Invasive Early Diagnosis and Prognosis determines the significance of clinical validation approaches for several markers. This book examines the use of noninvasive or minimally invasive molecular cancer markers that are under development or currently in use. It deals with a majority of commonly prevalent cancers and can help anyone working in the health-care industry to recommend or develop early diagnostics, at-risk tests, and prognostic biomarkers for various cancers.
It explores the practice of determining biomarkers by their characteristics and relative methodologies, and presents the most recent data as well as a number of current and upcoming early diagnostic noninvasive molecular markers for many common cancers. It also considers the sensitivity and specificity of markers, biomarker market, test providers, and patent information.
Approximately 30-35 Cancer Specific Noninvasive Molecular Diagnostic Markers in a Single Volume
The book details the general and technical aspects of noninvasive cancer markers. It covers imaging, cutting-edge molecular technologies for biomarker development, and noninvasive or minimally invasive sources of molecular markers, as well as quality control and ethical issues in cancer biomarker discovery. It also provides a detailed account of brain, head and neck, and oral cancer markers, and provides information on a number of gastrointestinal cancers, lung cancer, and mesothelioma markers.
Emphasizes the Importance of Volatile Markers in Early Cancer Diagnosis
- Presents noninvasive early molecular markers in urological cancers
- Describes gynecological and endocrine cancer markers
- Details noninvasive markers of breast, ovarian, cervical, and thyroid cancers
- Addresses hematological malignancies
- Contains information on noninvasive molecular markers in myelodysplastic syndromes, acute myeloid leukemia, Hodgkin's lymphoma, and multiple myeloma
- Provides comprehensive information on diagnostic and prognostic biomarkers in cutaneous melanoma
This text considers molecular technologies for biomarker development, noninvasive or minimally invasive sources of molecular markers, and quality control and ethical issues in cancer biomarker discovery.
Debmalya Barh (MSc, MTech, MPhil, PhD, PGDM) is the founder and president of the Institute of Integrative Omics and Applied Biotechnology (IIOAB), India. He is a consultant biotechnologist and an active researcher in integrative omics-based biomarkers, targeted drug discovery, and personalized medicine in cancer, neurodisorders, and cardiovascular, infectious, and metabolic diseases. He works with nearly 400 esteemed researchers from 30-35 countries and he has more than 100 high-impact publications. He has edited ten books in the field of omics. He also serves as an editorial and review board member for several highly respected international journals.
Dr. Angelo Carpi
is a clinical professor of medicine at the Pisa University Medical School, Pisa, Italy. He received his MD and postgraduate diplomas in internal medicine and nuclear medicine from the University of Pisa and his diploma of qualification on peptide hormones from the Collegio Medico Giuridico-Scuola Normale Superiore and the Scuola Superiore Sant'Anna, Pisa, Italy. His clinical practice and research included thyroid and breast tumors. He has authored about 300 publications included in PubMed. He is a member of the editorial boards of international journals such as Biomedicine & Pharmacotherapy and Frontiers in Bioscience.
Dr. Mukesh Verma
is a program director and chief in the Methods and Technologies Branch (MTB), Epidemiology and Genomics Research Program (EGRP) of the Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute (NCI), National Institutes of Health (NIH). Dr. Verma received his MSc from Pantnagar University and his PhD from Banaras Hindu University. He did postdoctoral research at George Washington University and was a faculty member at Georgetown University. He has published 128 research articles, book chapters, and reviews, and has edited three books in the field of cancer epigenetics and epidemiology.
Mehmet Gunduz, MD, PhD
, is a professor of otolaryngology and medical genetics, Faculty of Medicine, Turgut Ozal University, Turkey. He graduated from Medical School Hacettepe University in 1990, and completed his residency in otolaryngology at the same university. He received his PhD from Okayama University and Wakayama Medical University, Japan, and is medical board certified from both the Turkish and Japanese certification authorities. One of the pioneers in identifying ING family tumor suppressors, Dr. Gunduz has contributed to more than 150 international publications, 3,000 citations, several book chapters, and over 200 presentations in national and international conferences.
